본문 바로가기
KERD
논문KCI 등재

Anti‐SOX1 Antibodies in Paraneoplastic Neurological Syndrome

Hui Sun|Xuan Sun|Jiping Tan|Yan Liua|Weiping Guan|Jianjun Jia|Zhenfu Wang
대한신경과학회 (Korean Neurological Association)|2020.10|Journal of Clinical Neurology|제16권 제4호|pp. 530-546|DOI https://doi.org/10.3988/jcn.2020.16.4.530

2

조회

0

다운로드

2

인용

0

참고문헌

키워드

antibodiesSOXB1 transcription factorsparaneoplastic cerebellar degenerationsmall cell lung carcinomacarcinomanon-small-cell lung.

초록

Anti-Sry-like high mobility group box (SOX) 1 antibodies (abs) are partly characterized onconeural autoantibodies (autoabs) due to their correlation with neoplastic diseases. Anti- SOX1 abs are associated with various clinical manifestations, including Lambert-Eaton myasthenic syndrome (LEMS) and paraneoplastic cerebellar degeneration (PCD). However, the clinical characteristics of patients with anti-SOX1 abs have not been described in detail. This review systematically explores the reported patients with anti-SOX1 abs and analyzes these cases for demographic characteristics, clinical features, coexisting neuronal autoabs, neuroimaging findings, treatment, and clinical outcomes. In addition, considering that PCD is the most common paraneoplastic neurological syndrome and that the association between PCD and anti-SOX1 abs remains unclear, we focus on the presence of autoabs in relation to PCD and associated tumors. PCD-associated autoabs include various intracellular autoabs (e.g., anti-Hu, anti-Yo, anti-Ri, and anti-SOX1) and cell-surface autoabs (anti-P/Q-type voltage-gated calcium channel). Commonly involved tumors in PCD are small-cell lung cancer (SCLC), gynecological, and breast tumors. LEMS is the most common clinical symptom in patients with anti- SOX1 abs, followed by PCD, and multiple neuronal autoabs coexist in 47.1% of these patients. SCLC is still the predominant tumor in patients with anti-SOX1 abs, while non-SCLC is uncommon. No consistent imaging feature is found in patients with anti-SOX1 abs, and there is no consensus on either the therapy choice or therapeutic efficacy. In conclusion, the presence of anti-SOX1 abs alone is a potential predictor of an uncommon paraneoplastic neurological disorder, usually occurring in the setting of LEMS, PCD, and SCLC. The detection of anti-SOX1 abs contributes to an early diagnosis of underlying tumors, given the diversity of clinical symptoms and the absence of characteristic neuroimaging features.

Abstract

Anti-Sry-like high mobility group box (SOX) 1 antibodies (abs) are partly characterized onconeural autoantibodies (autoabs) due to their correlation with neoplastic diseases. Anti- SOX1 abs are associated with various clinical manifestations, including Lambert-Eaton myasthenic syndrome (LEMS) and paraneoplastic cerebellar degeneration (PCD). However, the clinical characteristics of patients with anti-SOX1 abs have not been described in detail. This review systematically explores the reported patients with anti-SOX1 abs and analyzes these cases for demographic characteristics, clinical features, coexisting neuronal autoabs, neuroimaging findings, treatment, and clinical outcomes. In addition, considering that PCD is the most common paraneoplastic neurological syndrome and that the association between PCD and anti-SOX1 abs remains unclear, we focus on the presence of autoabs in relation to PCD and associated tumors. PCD-associated autoabs include various intracellular autoabs (e.g., anti-Hu, anti-Yo, anti-Ri, and anti-SOX1) and cell-surface autoabs (anti-P/Q-type voltage-gated calcium channel). Commonly involved tumors in PCD are small-cell lung cancer (SCLC), gynecological, and breast tumors. LEMS is the most common clinical symptom in patients with anti- SOX1 abs, followed by PCD, and multiple neuronal autoabs coexist in 47.1% of these patients. SCLC is still the predominant tumor in patients with anti-SOX1 abs, while non-SCLC is uncommon. No consistent imaging feature is found in patients with anti-SOX1 abs, and there is no consensus on either the therapy choice or therapeutic efficacy. In conclusion, the presence of anti-SOX1 abs alone is a potential predictor of an uncommon paraneoplastic neurological disorder, usually occurring in the setting of LEMS, PCD, and SCLC. The detection of anti-SOX1 abs contributes to an early diagnosis of underlying tumors, given the diversity of clinical symptoms and the absence of characteristic neuroimaging features.

참고문헌 (99)

  1. Dalmau J, "Paraneoplastic syndromes of the CNS", Lancet Neurol, 7, pp.327~340 (2008)
  2. Iorio R, "Essentials of cerebellum and cerebellar disorders", pp.587~593 (2016), Springer
  3. Bentea G, "Autoimmune paraneoplastic syndromes associated to lung cancer : a systematic review of the literature : Part 3 : neurological paraneoplastic syndromes, involving the central nervous system", Lung Cancer, 106, pp.83~92 (2017)
  4. Giometto B, "Paraneoplastic neurologic syndrome in the PNS Euronetwork database : a European study from 20 centers", Arch Neurol, 67, pp.330~335 (2010)
  5. Dalmau J, "Antibody-Mediated Encephalitis", N Engl J Med, 378, pp.840~851 (2018)
  6. Graus F, "Anti-glial nuclear antibody : marker of lung cancer-related paraneoplastic neurological syndromes", J Neuroimmunol, 165, pp.166~171 (2005)
  7. Sabater L, "SOX1antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome", Neurology, 70, pp.924~928 (2008)
  8. Wegner M, "From head to toes : the multiple facets of Sox proteins", Nucleic Acids Res, 27, pp.1409~1420 (1999)
  9. Schepers GE, "Twenty pairs of Sox : extent, homology, and nomenclature of the mouse and human Sox transcription factor gene families", Dev Cell, 3, pp.167~170 (2002)
  10. Malas S, "Cloning and mapping of the human SOX1 : a highly conserved gene expressed in the developing brain", Mamm Genome, 8, pp.866~868 (1997)
  11. Titulaer MJ, "SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome : frequency and relation with survival", J Clin Oncol, 27, pp.4260~4267 (2009)
  12. Ruiz-García R, "Caveats and pitfalls of SOX1autoantibody testing with a commercial line blot assay in paraneoplastic neurological investigations", Front Immunol, 10, pp.769~ (2019)
  13. Kanaji N, "Paraneoplastic syndromes associated with lung cancer", World J Clin Oncol, 5, pp.197~223 (2014)
  14. Güre AO, "Serological identification of embryonic neural proteins as highly immunogenic tumor antigens in small cell lung cancer", Proc Natl Acad Sci U S A, 97, pp.4198~4203 (2000)
  15. Hardy-Werbin M, "Assessment of neuronal autoantibodies in patients with small cell lung cancer treated with chemotherapy with or without ipilimumab", Oncoimmunology, 7, pp.e1395125~ (2017)
  16. Sabater L, "Antibody repertoire in paraneoplastic cerebellar degeneration and small cell lung cancer", PLoS One, 8, pp.e60438~ (2013)
  17. 조희진, "Encephalitis with Anti-SOX1 Antibodies Presenting with New-Onset Refractory Status Epilepticus", Journal of Clinical Neurology, 15(4), pp.564~565 (2019), 대한신경과학회
  18. Berger B, "Prevalence of anti-SOX1 reactivity in various neurological disorders", J Neurol Sci, 369, pp.342~346 (2016)
  19. Li N, "Epigenetic inactivation of SOX1 promotes cell migration in lung cancer", Tumour Biol, 36, pp.4603~4610 (2015)
  20. Dogan Onugoren M, "Limbic encephalitis due to GABAB and AMPA receptor antibodies : a case series", J Neurol Neurosurg Psychiatry, 86, pp.965~972 (2015)
  21. Stich O, "SOX1antibodies in sera from patients with paraneoplastic neurological syndromes", Acta Neurol Scand, 125, pp.326~331 (2012)
  22. Mitoma H, "Immune-mediated cerebellar ataxias : practical guidelines and therapeutic challenges", Curr Neuropharmacol, 17, pp.33~58 (2019)
  23. Hadjivassiliou M, "Immune-mediated acquired ataxias", Handb Clin Neurol, 103, pp.189~199 (2012)
  24. Shams'ili S, "Paraneoplastic cerebellar degeneration associated with antineuronal antibodies : analysis of 50 patients", Brain, 126, pp.1409~1418 (2003)
  25. Alessandro L, "Cerebellar ataxia with extreme photophobia associated with anti-sox1 antibodies", Neurohospitalist, 9, pp.165~168 (2019)
  26. Alcock J, "Expression of Sox1, Sox2 and Sox9 is maintained in adult human cerebellar cortex", Neurosci Lett, 450, pp.114~116 (2009)
  27. Alcock J, "Dynamic distribution and stem cell characteristics of Sox1-expressing cells in the cerebellar cortex", Cell Res, 19, pp.1324~1333 (2009)
  28. Venkatraman A, "Paraneoplastic cerebellar degeneration with anti-Yo antibodies-a review", Ann Clin Transl Neurol, 3, pp.655~663 (2016)
  29. Mitoma H, "Immune-mediated cerebellar ataxias : from bench to bedside", Cerebellum Ataxias, 4, pp.16~ (2017)
  30. Ducray F, "Seronegative paraneoplastic cerebellar degeneration : the PNS Euronetwork experience", Eur J Neurol, 21, pp.731~735 (2014)
  31. Hasadsri L, "Anti-Yo associated paraneoplastic cerebellar degeneration in a man with large cell cancer of the lung", Case Rep Neurol Med, 2013, pp.725936~ (2013)
  32. Huemer F, "Anti-Hu antibody associated paraneoplastic cerebellar degeneration in head and neck cancer", BMC Cancer, 15, pp.996~ (2015)
  33. Graus F, "P", Q type calcium-channel antibodies in paraneoplastic cerebellar de-generation with lung cancer, 2002, pp.59, 764~766
  34. Cai G, "Non-small cell lung cancer associated with late-onset Lambert-Eaton myasthenic syndrome and paraneoplastic cerebellar degeneration", Neurol Sci, 41, pp.1277~1279 (2020)
  35. Bruylant K, "Probably anti-Tr associated paraneoplastic cerebellar degeneration as initial presentation of a squamous cell carcinoma of the lung", Clin Neurol Neurosurg, 108, pp.415~417 (2006)
  36. Sabater L, "Protein kinase Cgamma autoimmunity in paraneoplastic cerebellar degeneration and non-small-cell lung cancer", J Neurol Neurosurg Psychiatry, 77, pp.1359~1362 (2006)
  37. Hiasa Y, "Complicated paraneoplastic neurological syndromes : a report of two patients with small cell or non-small cell lung cancer", Clin Neurol Neurosurg, 106, pp.47~49 (2003)
  38. Konishi J, "Paraneoplastic cerebellar degeneration(PCD)associated with squamous cell carcinoma of the lung", Intern Med, 43, pp.602~606 (2004)
  39. Day J, "Paraneoplastic cerebellar degeneration associated with squamous cell carcinoma of the lung", J Clin Neurosci, 20, pp.1448~1449 (2013)
  40. Li C, "Anti-SOX1 antibodypositive paraneoplastic neurological syndrome presenting with Lambert-Eaton myasthenic syndrome and small cell lung cancer: a case report", Thorac Cancer, 11, pp.465~469 (2020)
  41. Mirallas O, "A rare case of long-term paraesthesia diagnosed as a paraneoplastic syndrome by anti-SOX1 antibody determination", BMJ Case Rep, 12, pp.e228916~ (2019)
  42. Ge FF, "Clinical, electrophysiological profile and prognosis in paraneoplastic syndrome with SRY-like high-mobility group superfamily of developmental transcription factors 1 antibody", Chin J Neurol, 52, pp.104~109 (2019)
  43. Liu L, "A case of myasthenia gravis as a paraneoplastic syndrome and sensory peripheral neuropathy with anti-SOX1 antibodies", Chin J Neurol, 50, pp.683~685 (2017)
  44. Ji MH, "Paraneoplastic cerebellar degeneration in anti-SOX1 antibodies : a case report and literature review", J Apoplexy Nerv Dis, 7, pp.651~653 (2019)
  45. Graus F, "Neuronal surface antigen antibodies in limbic encephalitis : clinical-immunologic associations", Neurology, 71, pp.930~936 (2008)
  46. Tschernatsch M, "Anti-SOX1 antibodies in patients with paraneoplastic and nonparaneoplastic neuropathy", J Neuroimmunol, 226, pp.177~180 (2010)
  47. Vural B, "Frequency of SOX Group B (SOX1, 2, 3) and ZIC2 antibodies in Turkish patients with small cell lung carcinoma and their correlation with clinical parameters", Cancer, 103, pp.2575~2583 (2005)
  48. Zekeridou A, "Paraneoplastic autoimmunity and small-cell lung cancer : neurological and serological accompaniments", Thorac Cancer, 10, pp.1001~1004 (2019)
  49. Titulaer MJ, "Clinical Dutch-English Lambert-Eaton myasthenic syndrome (LEMS) tumor association prediction score accurately predicts smallcell lung cancer in the LEMS", J Clin Oncol, 29, pp.902~908 (2011)
  50. Zoccarato M, "Diagnostics of paraneoplastic neurological syndromes", Neurol Sci, 38, pp.237~242 (2017)
  51. Kacem M, "Paraneoplastic limbic encephalitis revealing a small cell carcinoma of the lung", Respir Med Case Rep, 26, pp.157~160 (2018)
  52. Zuliani L, "Paraneoplastic limbic encephalitis associated with potassium channel antibodies : value of anti-glial nuclear antibodies in identifying the tumour", J Neurol Neurosurg Psychiatry, 78, pp.204~205 (2007)
  53. Höftberger R, "Encephalitis and AMPA receptor antibodies : novel findings in a case series of 22 patients", Neurology, 84, pp.2403~2412 (2015)
  54. Höftberger R, "Encephalitis and GABAB receptor antibodies : novel findings in a new case series of 20 patients", Neurology, 81, pp.1500~1506 (2013)
  55. Fukuda TG, "Multiple paraneoplastic antibodies (anti-SOX1, anti-Hu, and anti-Amphiphysin) detected in a patient with limbic encephalitis and small cell lung cancer", Neurol India, 65, pp.1127~1128 (2017)
  56. Boronat A, "GABA(B) receptor antibodies in limbic encephalitis and anti-GAD-associated neurologic disorders", Neurology, 76, pp.795~800 (2011)
  57. Lai M, "AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location", Ann Neurol, 65, pp.424~434 (2009)
  58. Ueno T, "Integrated treatment for autonomic paraneoplastic syndrome improves performance status in a patient with small lung cell carcinoma : a case report", BMC Neurol, 18, pp.189~ (2018)
  59. Zhang YT, "A case of cancerous LambertEaton syndrome with SOXl antibody positive", J Neurosci Ment Health, 16, pp.735~737 (2016)
  60. Jeffery OJ, "GABAB receptor autoantibody frequency in service serologic evaluation", Neurology, 81, pp.882~887 (2013)
  61. Dik A, "Onconeural antigen spreading in paraneoplastic neurological disease due to small cell lung cancer", Oxf Med Case Reports, 2018, pp.omy034~ (2018)
  62. Nelson HH, "Key epigenetic changes associated with lung cancer development : results from dense methylation array profiling", Epigenetics, 7, pp.559~566 (2012)
  63. Saraya AW, "Differences and diversity of autoimmune encephalitis in 77 cases from a single tertiary care center", BMC Neurol, 19, pp.273~ (2019)
  64. Horta ES, "Neural autoantibody clusters aid diagnosis of cancer", Clin Cancer Res, 20, pp.3862~3869 (2014)
  65. Kunstreich M, "Paraneoplastic limbic encephalitis with SOX1 and PCA2antibodies and relapsing neurological symptoms in an adolescent with Hodgkin lymphoma", Eur J Paediatr Neurol, 21, pp.661~665 (2017)
  66. Dubey D, "Autoimmune CRMP5 neuropathy phenotype and outcome defined from 105 cases", Neurology, 90, pp.e103~e110 (2018)
  67. Chen DS, "Oncology meets immunology : the cancer-immunity cycle", Immunity, 39, pp.1~10 (2013)
  68. McKeon A, "Paraneoplastic encephalomyelopathies : pathology and mechanisms", Acta Neuropathol, 122, pp.381~400 (2011)
  69. Grativvol RS, "Updates in the Diagnosis and Treatment of Paraneoplastic Neurologic Syndromes", Curr Oncol Rep, 20, pp.92~ (2018)
  70. Corsini E, "Intrathecal synthesis of onconeural antibodies in patients with paraneoplastic syndromes", J Neuroimmunol, 290, pp.119~122 (2016)
  71. Graus F, "Recommended diagnostic criteria for paraneoplastic neurological syndromes", J Neurol Neurosurg Psychiatry, 75, pp.1135~1140 (2004)
  72. de Andrés C, "Unusual magnetic resonance imaging and cerebrospinal fluid find-ings in paraneoplastic cerebellar degeneration : a sequential study", J Neurol Neurosurg Psychiatry, 77, pp.562~563 (2006)
  73. Choi KD, "Cerebellar hypermetabolism in paraneoplastic cerebellar degeneration", J Neurol Neurosurg Psychiatry, 77, pp.525~528 (2006)
  74. Mitoma H, "Guidelines for treatment of immune-mediated cerebellar ataxias", Cerebellum Ataxias, 2, pp.14~ (2015)
  75. Lipka AF, "SOX1 antibodies in LambertEaton myasthenic syndrome and screening for small cell lung carcinoma", Ann N Y Acad Sci, 1275, pp.70~77 (2012)
  76. Paz-Ares L, "PL02. 11 Overall survival with durvalumab plus etoposide-platinum in first-line extensive-stage SCLC : results from the CASPIAN study", J Thorac Oncol, 14, pp.S7~S8 (2019)
  77. Le May M, "Anti-Yo antibody-mediated paraneoplastic cerebellar degeneration associated with cognitive affective syndrome in a patient with breast cancer : a case report and literature review", Curr Oncol, 25, pp.e585~e591 (2018)
  78. Finsterer J, "Deterioration of anti-Yo-associated paraneoplastic cerebellar degeneration", J Neurol Sci, 308, pp.139~141 (2011)
  79. Debes JD, "Anti-Yo-associated paraneoplastic cerebellar degeneration in a man with adenocarcinoma of the gastroesophageal junction", Dig Surg, 24, pp.395~397 (2007)
  80. Meglic B, "Anti-Yo-associated paraneoplastic cerebellar degeneration in a man with gastric adenocarcinoma", J Neurol Sci, 185, pp.135~138 (2001)
  81. Sutton IJ, "Anti-Yo antibodies and cerebellar degeneration in a man with adenocarcinoma of the esophagus", Ann Neurol, 49, pp.253~257 (2001)
  82. Matschke J, "Paraneoplastic cerebellar degeneration and anti-Yo antibodies in a man with prostatic adenocarcinoma", J Neurol Neurosurg Psychiatry, 78, pp.775~777 (2007)
  83. Tanriverdi O, "Anti-Yo antibody-mediated paraneoplastic cerebellar degeneration in a female patient with pleural malignant mesothelioma", Jpn J Clin Oncol, 43, pp.563~568 (2013)
  84. Mirouse A, "Sudden death occurring after anti-Hu associated paraneoplastic cerebellar degeneration and dysautonomia revealing a small cell lung carcinoma", Rev Med Interne, 35, pp.757~759 (2014)
  85. Storstein A, "Prostate cancer, Hu antibodies and paraneoplastic neurological syndromes", J Neurol, 263, pp.1001~1007 (2016)
  86. Tsukamoto T, "Paraneoplastic cerebellar degeneration and limbic encephalitis in a patient with adenocarcinoma of the colon", J Neurol Neurosurg Psychiatry, 56, pp.713~716 (1993)
  87. de la Sayette V, "Paraneoplastic cerebellar syndrome and optic neuritis with anti-CV2antibodies : clinical response to excision of the primary tumor", Arch Neurol, 55, pp.405~408 (1998)
  88. Honnorat J, "Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2", CRMP5 antibodies, 2009, pp.80, 412~416
  89. Aliprandi A, "Paraneoplastic cerebellar degeneration with antiCV2", CRMP5 antibodies and prostate adenocarcinoma, 2015, pp.36, 1501~1503
  90. Brieva-Ruíz L, "Anti-Ri-associated paraneoplastic cerebellar degeneration and breast cancer : an autopsy case study", Clin Neurol Neurosurg, 110, pp.1044~1046 (2008)
  91. Bazine A, "Occult breast carcinoma presenting with anti-Ri-associated paraneoplastic cerebellar degeneration revealed with FDG-PET", Cancer Clin Oncol, 4, pp.9~13 (2014)
  92. Mancuso M, "Anti-Ri-associated paraneoplastic cerebellar degeneration. Report of a case and revision of the literature", Arch Ital Biol, 149, pp.318~322 (2011)
  93. Ameneiros-Lago E, "Paraneoplastic cerebellar degeneration associated with anti-Ma2 antibodies", Med Clin (Barc), 147, pp.e55~e56 (2016)
  94. Bataller L, "Antibodies to Zic4 in paraneoplastic neurologic disorders and smallcell lung cancer", Neurology, 62, pp.778~782 (2004)
  95. Sabater L, "ZIC antibodies in paraneoplastic cerebellar degeneration and small cell lung cancer", J Neuroimmunol, 201-202, pp.163~165 (2008)
  96. Pavolucci L, "Paraneoplastic cerebellar degeneration and lambert-eaton myasthenia in a patient with merkel cell carcinoma and voltagegated calcium channel antibodies", Muscle Nerve, 56, pp.998~1000 (2017)
  97. Zhang C, "Paraneoplastic cerebellar degeneration associated with noncutaneous Merkel cell carcinoma", Neurol Neuroimmunol Neuroinflamm, 1, pp.e17~ (2014)
  98. Sillevis Smitt P, "Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor", N Engl J Med, 342, pp.21~27 (2000)
  99. Lancaster E, "Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen", Lancet Neurol, 9, pp.67~76 (2010)

관련 논문AI추천

Gait Disturbance as an Initial Manifestation of the Paraneoplastic Neurologic Syndrome in a Patient with Lung Cancer김은석, 김창범, 김창환, 박찬혁, 이주성, 이현성, 정한영대한근전도전기진단의학회 · 대한근전도 전기진단의학회지2020 · 제22권 제2호항Hu 및 항SOX1자가항체가 동시에 확인된 아테졸리주맙 연관 자가면역뇌염은미연, 하형석, 황재춘대한신경과학회 · 대한신경과학회지2024 · 제42권 제1호Anti-Ri-Antibody-Associated Paraneoplastic Syndrome in a Man with Breast Cancer Showing a Reversible Pontine Lesion on MRI김광국, 김희영, 임영민대한신경과학회 · Journal of Clinical Neurology2009 · 제5권 제3호Paraneoplastic Neurologic Syndrome in Small Cell Lung Carcinoma김창환, Joa Kyung-Lim, Jung Han-Young, Kim Myeong-Ok, Ku Young-Su, Lee Young-Gon대한근전도전기진단의학회 · 대한근전도 전기진단의학회지2023 · 제25권 제2호Seropositive Myasthenia Gravis Associated with Small-Cell Lung Carcinoma오신중, 정두신, Masayuki Ohira대한신경과학회 · Journal of Clinical Neurology2011 · 제7권 제1호A Case of Lambert-Eaton Myasthenic Syndrome with Small-Cell Lung Cancer and Transient Increase in Anti-Acetylcholine-Receptor-Binding Antibody Titer김승민, 신하영, 이정환, 선우일남대한신경과학회 · Journal of Clinical Neurology2012 · 제8권 제4호

이 간행물의 다른 논문 (33건)

Clinical Approach to Autoimmune Epilepsy김대영, 이순태, 조용원, 서종근, 강경욱, 노영주, 김동욱, 김근태, 장윤혁, 변정익, 양광익pp. 519-529Antiepileptic Drug Selection According to Seizure Type in Adult Patients with Epilepsy김혜윤, 노영주, 김동욱, 김근태, 김대영, 강경욱, 서종근, 조용원, 이순태, 양광익, 변정익pp. 547-555Pharmacological Treatment of Epilepsy in Elderly Patients김대영, 김근태, 김동욱, 노영주, 서종근, 변정익, 양광익, 이순태, 조용원, 강경욱pp. 556-561Paramagnetic Rims in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder: A Quantitative Susceptibility Mapping Study with 3-T MRI신나영, 이광수, 김우준, 남윤호, 안재영, 김범수, 최양신, 장진희, 안국진pp. 562-572Altered Structural Network in Newly Onset Childhood Absence Epilepsy염미선, 이진성, 고태성, 김은희, 윤희망, 심우현pp. 573-580
원문 보기